Evidence map›Paper›PMID 42311936›Full record

ArticleCancer heterogeneity and plasticity2026

Keratin 5 expression defines a niche-supported hierarchy in tubo-ovarian cancer.

Zhiyu Tian, Karen McLean

Abstract read
In one paragraph

Article in Cancer heterogeneity and plasticity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhiyu TianDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Karen McLeanDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

Funding

Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA DamageR01CA251198 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCLEAN, KAREN · 2020 to 2024
$1.9M
NCI NIH HHS R01 CA251198
6 · The paper itself

Abstract

Tubo-ovarian high-grade serous carcinoma (HGSC) is characterized by extreme cellular heterogeneity. A tumorigenic subset of cancer-propagating cells (CPC) with stem-like properties coexists with a large population of non-cancer-propagating cells (non-CPC), but the functional interplay between these two cell types remains poorly understood. In this issue, Bidarimath et al. identify keratin 5 (KRT5) as a marker of CPC in HGSC and propose a niche model in which osteopontin (OPN) sustains KRT5-positive CPC through interactions with KRT5-negative, non-tumorigenic cells. By combining in vitro, in vivo, and patient-derived data, the study links a supportive tumor microenvironment to the maintenance of a phenotypically defined CPC population.

Identifiers

PMID42311936
PMCPMC13271655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.